marked.bio

anti-CD161 antibody ยท antibody

IMT-009

1 active trials across 2 of our biomarkers, targeting CD161. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 1 1 Phase 1/2
MSI-H / dMMR 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of IMT-009.

  1. Immunitas Therapeutics 1

Trials

1 of 1 trials shown

  1. Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

    Active, not recruiting Phase 1/2 Immunitas Therapeutics Started 2022Primary completion 2026-01 NCT05565417

    IMT-009fruquintinib

    a PARPi for patients with gBRCA mutations

    BRCA1/2 mutationMSI-H / dMMRNon Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma